Effect of Metformin in Patients of Polycystic Ovarian Disease (PCOD), a Comparative & Observational Study

International Journal of Medical Science

© 2015 by SSRG - IJMS Journal

Volume 2 Issue 10

Year of Publication : 2015

Authors : Dr. Jayshree Awalekar, Dr. Chidanand Awalekar, Dr. Vidya M. Jadhav, Dr. C. G. Chivate and Dr. M. H. Patwardhan

10.14445/23939117/IJMS-V2I10P101

How to Cite?

Dr. Jayshree Awalekar, Dr. Chidanand Awalekar, Dr. Vidya M. Jadhav, Dr. C. G. Chivate and Dr. M. H. Patwardhan, "Effect of Metformin in Patients of Polycystic Ovarian Disease (PCOD), a Comparative & Observational Study," SSRG International Journal of Medical Science, vol. 2,  no. 10, pp. 1-4, 2015. Crossref, https://doi.org/10.14445/23939117/IJMS-V2I10P101

Abstract:

Polycystic ovarian disease (PCOD) is common endocrine disorder. Majority of young females are affected.Insulin resistance along with dysfunction of hypothalamopituitoryadrenal axis is a key etiological factor in development of all manifestations of PCOD1. They present with irregular menses, infertility, obesity, Hirsutism, Acanthosis Nigricans etc. Insulin resistance increases the chance of the metabolic syndrome, which increases chance of developing diabetes mellitus, heart disease, obesity, hypertension and increased levels of cholesterol1,8,9. Metformin is one of the widely accepted treatment modality allover the world 1,5. we aimed to study efficacy of Metformin in PCOS. Here cases are diagnosed by using Rotterdam’s criteria. We recruited 35 cases PCOD. BMI, Menstrual irregularity, infertility, Hirsutism, Acanthosis Nigricans, acne were common presenting features. Hormonal & biochemical profile was studied S.LH (Luteinizing Hormone), FSH (Follicle stimulating hormone), levels, Serum Insulin levels. Weight loss, menstrual regularity, LH/FSH Ratio,HOMA Index were studied initially & compared all parameters after 3 months of treatment with Metformin. Our study shows that, BMI was reduced from mean 29.64 to 27.13 after 3 months of Metformin treatment which is highly significant(p0.0000).LH/FSH ratio was mean 2.56,dropped to 1.70,(p0.000) after treatment, which is significant. HOMA index values before treatment were mean 25.85, & after treatment it was 15.21(p0.000) highly significant. Hyperprolactinemia corrected from Mean 24.11 to16.92 to 6.27 (p0.004) found to be statistically significant. The present study gives us idea about efficacy of Metformin treatment in PCOD cases & will be useful in patient treatment schedules.

Keywords:

PCOD (Polycystic ovarian Disease),Insulin Resistance(IR),Hyperinsulinemia, Metformin, BMI Body Mass Index),LH/FSH-Luteinizing hormone & Follicle stimulating hormone ratio,HOMA index- Homeostatic model assessment.

References:

[1]. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647–54.
[2]. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin onspontaneous and clomiphene-induced ovulation in the polycystic ovarysyndrome. N Engl J Med 1998;338:1876–80.
[3]. Batukan C, Baysal B. Metformin improves ovulation and pregnancy ratesin patients with polycystic ovary syndrome. Arch Gynecol Obstet 2001;265:124–27.
[4]. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. Jan 2004;81(1):19-25.
[5]. Goodarzi MO, Korenman SG. The importance of insulin resistance inpolycystic ovary syndrome. FertilSteril 2003;80:255–58.
[6]. Alemzadeh R, Kichler J, Calhoun M. Spectrum of metabolic dysfunction in relationship with hyperandrogenemia in obese adolescent girls with polycystic ovary syndrome. Eur J Endocrinol. Jun 2010;162(6):1093-9.
[7]. Otta CF, Wior M, Iraci GS, Kaplan R, Torres D, Gaido MI, et al. Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, doubleblind, and placebo control trial. GynecolEndocrinol. Mar 2010;26(3):173-8.
[8]. Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK, Guzick DS. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. FertilSteril. Aug 2004;82(2):421- 9.
[9]. Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with polycystic ovary syndrome. Metabolism 1999; 48:1-10.
[10]. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, longterm clinical evaluation. J ClinEndocrinolMetab. Jan 2000;85(1):139-46.
[11]. Barber TM, McCarthy MI, Wass JA, Franks S. Obesity and polycystic ovary syndrome. ClinEndocrinol (Oxf). Aug 2006;65(2):137-45.
[12]. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000;132:989–993.
[13]. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393- 403.
[14]. Kitabchi AE, Temprosa M, Knowler WC, et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle Metformin in polycystic ovary syndrome: systematic review and meta-analysis.
[15] Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and metaanalysis. BMJ. Oct 25 2003;327(7421):951-3.